Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
RESEARCH TOOLSreports
Foghorn Therapeutics (FHTX) Stock Price & Analysis
95 Followers
FHTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.70 - $9.97
Previous Close$6.37
Volume87.61K
Average Volume (3M)105.58K
Market Cap
$352.44M
Enterprise Value$163.46M
Total Cash (Recent Filing)$234.06M
Total Debt (Recent Filing)$45.07M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Aug 06, 2024EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding42,585,616
10 Day Avg. Volume80,518
30 Day Avg. Volume105,585
Standard Deviation0.36
R-Squared0.19
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-2.92
Price to Sales (P/S)6.61
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.79
Enterprise Value/Gross Profit4.79
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$20.00Price Target Upside231.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Foghorn Therapeutics News
Ownership Overview
14.33% Insiders
5.89% Mutual Funds
3.62% Other Institutional Investors
76.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $2.70 and its highest was $9.97 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Currently, no data Available
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 18 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on May 06, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.633 by $0.043.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -$0.64.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 55,328,655 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.633. Following the earnings report the stock price went down -2.671%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Among the largest hedge funds holding Foghorn Therapeutics’s share is Flagship Pioneering Inc.. It holds Foghorn Therapeutics’s shares valued at 85M.
---
Foghorn Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (231.13% Upside)
$20.00 (231.13% Upside)
Hedge Fund Trend
Decreased
By 63.3K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.61%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
---
FHTX Stock 12 Month Forecast
Average Price Target
$20.00
▲(231.13% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Aclaris Therapeutics
―
Crispr Therapeutics AG
―
Meiragtx Holdings
―
Best Analysts Covering FHTX
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-12.69%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -12.69% per trade.
---